The association of HLA/KIR genes with non-small cell lung cancer (adenocarcinoma) in a Han Chinese population

The host immune system plays a crucial role in the surveillance, recognition and elimination of tumor cells. Recent studies found that Human lymphocyte antigen class I (HLA I) genes, Killer cell immunoglobulin-like receptor (KIR) genes and HLA/KIR combinations play a role in the defense against tumor cells. To evaluated the associations between HLA I genes, KIR genes and HLA/KIR combinations and non-small cell lung cancer (NSCLC) in a Chinese Han population, a total of 229 patients with NSCLC (adenocarcinoma) and 217 healthy individuals were studied. Our results showed that the HLA-C*08:01 allele occurred at a significantly higher frequency in the NSCLCs compared with the controls (P=0.034). The HLA haplotype frequencies bearing HLA-A, -B, and -C loci between the NSCLC and control groups were not different (P>0.05). And there were no differences in the KIR gene, genotype and haplotype frequencies between the NSCLC and control groups (P>0.05). Also, there were no differences between the HLA/KIR combinations in the KIR3D genes and HLA-A3/A11, HLA-Bw4 ligands and KIR2D genes and HLA-C1/C2 ligands between the NSCLC and control groups (P>0.05). Our results indicate that the HLA-C*08:01 allele could be a risk factor for NSCLC (adenocarcinoma) in the Chinese Han population (OR=2.395; 95% CI: 1.359-4.221).
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

Authors: Lou M, Gao Z, Zhu T, Mao X, Wang Y, Yuan K, Tong J Abstract As a member of the tripartite motif family, tripartite motif-containing protein 59 (TRIM59) serves as an E3 ubiquitin ligase in various cellular processes, including intracellular signaling, development, apoptosis, protein quality control, innate immunity, autophagy and carcinogenesis. The present study aimed to investigate the expression and prognostic value of TRIM59 in patients with non-small cell lung cancer (NSCLC). Expression of TRIM59 in patients with NSCLC was measured by immunohistochemistry in tissue microarrays. Datasets from The Cancer...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
This study aimed to investigate the molecular and clinical patterns of HER2 mutations in advanced non‐small cell lung cancer (NSCLC), and compare the different outcomes between chemotherapy and HER2‐TKIs.MethodsAdvanced or recurrent non ‐small cell lung cancer patients with de novo HER2 mutations (N =  75) were included in this study. Molecular information, clinical features, and treatment outcomes were retrospectively collected from a web‐based patient registry and hospital chart review.ResultsBetween October 2012 and December 2018, 65 patients with in ‐frame insertion mutations, eight with point mutation...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
CONCLUSION: Long non-coding RNA DLEU1 is likely to represent an available biomarker or a potential therapeutic target in multiple tumors. PMID: 31969095 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Publication date: Available online 8 January 2020Source: Genes &DiseasesAuthor(s): Zhen Liu, Jiahao Liu, Yang Li, Hao Wang, Zixi Liang, Xiaojie Deng, Qiaofen Fu, Weiyi Fang, Ping XuAbstractThe presence of VPS33B in tumors has rarely been reported. Downregulated VPS33B protein expression is an unfavorable factor that promotes the pathogenesis of lung adenocarcinoma (LUAD). Overexpressed VPS33B was shown to reduce the migration, invasion, metastasis, and chemoresistance of LUAD cells to cisplatin (DDP) in vivo and in vitro. Mechanistic analyses have indicated that VPS33B first suppresses epidermal growth factor...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
Non-invasive discrimination between lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) subtypes of non-small-cell lung cancer (NSCLC) could be very beneficial to the patients unfit for the inva...
Source: BioMedical Engineering OnLine - Category: Biomedical Engineering Authors: Tags: Research Source Type: research
ConclusionThese results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD.Key pointsOur results suggest that ACTL8 serves an oncogenic role in human LUAD cells, and that ACTL8 may represent a potential therapeutic target for LUAD.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology. Individual tumor nodules can be easily measured by live animal imaging and the nodules can be harvested and isolated from surrounding lung tissu...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
In this study, the expression of PRKCZ-AS1 in LUAD tissues and cell lines was notably upregulated. Moreover, knockdown of PRKCZ-AS1 inhibited the proliferation and migration, but promoted apoptosis in LUAD cells. Furthermore, miR-766-5p could bind with PRKCZ-AS1. Besides, the expression miR-766-5p was negatively regulated by PRKCZ-AS1 expression in LUAD cells. Furtherly, PRKCZ-AS1 expression positively regulated the expression of MAPK1. Similarly, the expression of MAPK1 was negatively regulated by miR-766-5p expression. Moreover, the binding ability between miR-766-5p and MAPK1 was confirmed. Furthermore, knockdown of MAP...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide [1]. A significant proportion of patients with non-small cell lung cancer (NSCLC), particularly those with adenocarcinoma histology, carry EGFR mutations, with about 15% in Caucasian adenocarcinoma and 50% in Asian adenocarcinoma are EGFR mutants [1 –3]. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been established as the standard therapy in the first-line treatment of advanced NSCLC with EGFR mutations.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSIONS: We newly identified two NSCLC related variants on chromosome 5p15.33. Both TERT-rs33963617 and CLPTM1L-rs77518573 conferred reduced risk for NSCLC in Chinese Han population. PMID: 31935503 [PubMed - as supplied by publisher]
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | China Health | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study